MetaCap

LifeStance Health Group Inc. (LFST)

NASDAQ: LFSTHealth CareMedical/Nursing ServicesUSD

13.82+0.48 (+3.60%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LFST stock chart

Technical analysis

Key statistics

All statistics
52-week range
6.21 – 15.66
Day range
13.21 – 13.83
Volume / Avg
5.62M / 5.27M
Beta
—

52-week range

$6.21$15.66

LFST stock today

LifeStance Health Group (LFST) closed at $13.82 on Nov 20, up 3.60% (+$0.48), versus the S&P 500's 3.70% decline. Shares are 11.7% below their 52-week high of $15.66, set on Nov 5, 2026 and 122.7% above the 52-week low of $6.21, near the top of the past year's range. LFST is up 96.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 114.6%.

At 76.8x trailing earnings, LifeStance Health Group trades above the peer-group median of 22.9x. Its forward P/E of 30.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About LifeStance Health Group

Company profile

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder.

Industry
Medical/Nursing Services
CEO
Mr. David Patrick Bourdon
Headquarters
Scottsdale, AZ
Employees
8,863
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, LifeStance Health Group generated $1.42 billion in revenue, up 13.9% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $9.7 million, for a net margin of 0.7% versus a median of -17.6% in the prior 5 years. Operating margin was 1.7%.

LifeStance Health Group annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.42B$1.25B$1.06B$859.54M$667.51M
Growth+13.85%+18.50%+22.82%+28.77%+214.10%
Net income$9.66M$-57.44M$-186.26M$-215.56M$-307.20M
EPS (diluted)$0.02$-0.15$-0.51$-0.61$-1.05

Analyst forecast

Forecast

Consensus (11 analysts)

buy

Avg. price target

$16.80+21.56%

  • Strong buy 2
  • Buy 7
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.06 vs $0.03
Surprise
+100.00%

LFST news

All LFST news

LifeStance Health Group peers

Health Care sector
LFST peer companies
CompanyPrice% ChgMarket capCompare
OPCHOption Care Health Inc.31.59-0.06%$4.73Bvs LFST
HIMSHims & Hers Health Inc. Class A14.60-8.86%$3.42Bvs LFST
CHEChemed Corp548.59-0.50%$7.11Bvs LFST
PRVAPrivia Health Group Inc.25.05+1.46%$3.20Bvs LFST
AVAHAveanna Healthcare Holdings Inc.11.01+2.90%$2.40Bvs LFST
ADUSAddus HomeCare Corporation122.50+1.18%$2.28Bvs LFST
USPHU.S. Physical Therapy Inc.95.93+1.71%$1.43Bvs LFST
WGSGeneDx Holdings Corp. Class A45.46-7.68%$1.36Bvs LFST

Indexes, lists and sector

LifeStance Health Group stock FAQ

What is LifeStance Health Group's stock price today?

LFST last traded at $13.82 as of Nov 20, 4:00 PM EST, up 3.60% on the day. Prices are delayed at least 15 minutes.

What is LFST's P/E ratio?

LFST trades at a trailing P/E ratio of 76.78 and a forward P/E of 30.77, compared with a median of 22.9 for its closest peers.

Who is LifeStance Health Group's CEO?

Mr. David Patrick Bourdon is the chief executive officer of LifeStance Health Group Inc., which has about 8,863 employees.

What is the LFST 52-week high?

The 52-week high for LFST is $15.66 and the 52-week low is $6.21. The stock is currently 11.7% below its high.

Compare LFST